AstraZeneca's Alexion wins US accelerated approval for Ultomiris in IgA nephropathy

AstraZeneca's Alexion received US accelerated approval for Ultomiris as the first C5 inhibitor to reduce proteinuria in adults with IgA nephropathy, based on Phase III I CAN data showing a 43.4% reduction versus placebo at 34 weeks.

Detected & updated continuously · Source: Nebula